 SAN DIEGO , April 26, 2022 PRNewswire -- Evofem Biosciences, Inc., Nasdaq: EVFM today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists ACOG annual meeting. The poster presentation details the characterization of women who experienced urinary tract infections UTIs during the AMPOWER Study. 